Liposomal Doxorubicin and Thermal Therapy in Treating Patients With Prostate Cancer

This study has been completed.
Sponsor:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00061867
First received: June 5, 2003
Last updated: May 29, 2013
Last verified: July 2005

June 5, 2003
May 29, 2013
March 2003
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00061867 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Liposomal Doxorubicin and Thermal Therapy in Treating Patients With Prostate Cancer
A Dose Escalation, Pharmacokinetics, and Safety Study of Doxorubicin Encapsulated in Temperature Sensitive Liposomes Released Through Microwave Therapy in the Treatment of Prostate Cancer

RATIONALE: Drugs used in chemotherapy, such as liposomal doxorubicin, use different ways to stop tumor cells from dividing so they stop growing or die. Microwave thermotherapy kills tumor cells by heating them to several degrees above body temperature. Combining liposomal doxorubicin with microwave thermotherapy may kill more tumor cells.

PURPOSE: This phase I trial is studying the side effects and best dose of liposomal doxorubicin when given together with microwave thermotherapy in treating patients with prostate cancer.

OBJECTIVES:

  • Determine the maximum tolerated dose of doxorubicin HCl liposome released through thermal microwave therapy in patients with adenocarcinoma of the prostate.
  • Determine the pharmacokinetics and biodistribution profile of this drug in these patients.
  • Determine the safety profile and dose-limiting toxicity of this drug in these patients.
  • Determine the clinical response in patients treated with this regimen.

OUTLINE: This is an open-label, dose-escalation, multicenter study.

Patients receive doxorubicin HCl liposome IV over 30 minutes. Patients then undergo a 60-minute course of prostate thermotherapy. Treatment may repeat every 28-42 days for up to 6 courses, at the discretion of the physician.

Cohorts of 3-6 patients receive escalating doses of doxorubicin HCl liposome until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.

Patients are followed at 8, 15, 30, and 90 days.

PROJECTED ACCRUAL: Approximately 50 patients will be accrued for this study.

Interventional
Phase 1
Masking: Open Label
Primary Purpose: Treatment
Prostate Cancer
  • Drug: pegylated liposomal doxorubicin hydrochloride
  • Procedure: hyperthermia treatment
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
Not Provided
August 2005
Not Provided

DISEASE CHARACTERISTICS:

  • Histologically confirmed adenocarcinoma of the prostate
  • Rising prostate-specific antigen AND radiographic evidence of extraprostatic prostate cancer by bone scan, CT scan, prostascint scan, or MRI

PATIENT CHARACTERISTICS:

Age

  • 40 and over

Performance status

  • Karnofsky 80-100%

Life expectancy

  • Not specified

Hematopoietic

  • WBC greater than 4,000/mm^3
  • Platelet count greater than 100,000/mm^3
  • Hemoglobin greater than 10.0 g/dL

Hepatic

  • Bilirubin normal
  • AST normal
  • Alkaline phosphatase normal
  • No acute or chronic liver disease

Renal

  • Creatinine less than 1.5 times upper limit of normal

Cardiovascular

  • Ejection fraction at least 50% by MUGA
  • EKG normal
  • No myocardial infarction or cerebral vascular accident within the past 6 months
  • No life threatening cardiac arrhythmias
  • No congestive heart failure
  • No cardiac pacemaker
  • No peripheral arterial disease with intermittent claudication or Leriches syndrome (i.e., claudication of the buttocks or perineum)

Other

  • Fertile patients must use effective barrier contraception during and for 3 months after study participation
  • No sperm donation during and for 3 months after study participation
  • Not febrile
  • No interest in future fertility or fathering children
  • No significantly decreased pain response
  • No severe urethral stricture
  • No protruding median lobe resulting in a "ball-valve" type of obstruction at the bladder neck
  • No major psychiatric illness that would prevent informed consent
  • No major psychiatric illness that required inpatient treatment within the past 3 months
  • No psychological, family, sociological, or geographic condition that would preclude study compliance
  • No allergy to eggs or egg products
  • No urinary or prostatic infection
  • No full urinary retention
  • No penile or urinary sphincter implant
  • No metallic implants in the pelvic or femoral area
  • No other serious medical illness that would preclude study participation

PRIOR CONCURRENT THERAPY:

Biologic therapy

  • No concurrent live vaccines

Chemotherapy

  • No prior anthracycline
  • No concurrent streptozocin

Endocrine therapy

  • No concurrent hormonal therapy (except luteinizing hormone-releasing hormone analog)
  • No concurrent glucocorticoids administered at more than physiologic replacement doses (other than as an antiemetic)

Radiotherapy

  • Not specified

Surgery

  • More than 3 months since prior major surgery

Other

  • No prior therapy that resulted in permanent reduction of pain response (e.g., prior surgery, regional or local anesthetic)
  • No concurrent PC-SPES
  • No concurrent cyclosporine, phenobarbital, or phenytoin
Male
40 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00061867
CELSION-10302101, CDR0000301761, RPCI-DS-0228
Not Provided
Not Provided
Celsion
Not Provided
Study Chair: Catherine Van Doren, RN Celsion
National Cancer Institute (NCI)
July 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP